few side effects, Chi said.
“It’s well-tolerated, both from a side-effect profile and from a quality-of-life perspective,” Chi said, noting that side effects differ little from a placebo.
The second trial involved adding enzalutamide to androgen-deprivation therapy, and again positive results were found.
About 80% of men treated with enzalutamide were alive after three years, compared with 72% of men who received standard treatment, the researchers said.
Study co-chair Ian Davis is a professor at Monash University in Australia. “The actual result in patients starting hormonal therapy, noting patients had a 60% improvement in the time it takes to detect cancer growing again along with a 33% increase chance of survival, was far higher than we expected,” he said in a news release.
In that trial, 1,125 men were randomly assigned to